Cerevel plots first late-stage move as Pfizer drug comes through in PhII Parkinson's trial
One of the drugs that Cerevel Therapeutics has picked up from Pfizer’s neuroscience pipeline has shown promise in a Phase II trial, paving the way for a quick advance into pivotal Parkinson’s programs.
The biotech reported on Monday that oral tavapadon (formerly PF-06649751) beat placebo in helping patients with early-stage Parkinson’s disease achieve statistically significant improvement on a score measuring their motor symptoms. At week 15, the drug arm saw their score on the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale Part III drop by an average of 9.0, versus 4.3 for placebo. The least-square mean improvement was -4.8 in favor of tavapadon (p=0.0407).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
